RecruitingNot ApplicableNCT06617832

Trial Designs for Evaluating Migraine Treatment


Sponsor

University of Aarhus

Enrollment

128 participants

Start Date

Nov 13, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The study aims to test interactions between drug and placebo-responses in acute migraine treatment and to assess variation in adverse events according to treatment information provided. Using a clinical within-subjects, advanced balanced placebo design, patients with episodic migraine will receive six treatment conditions in a randomized order.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Active drug for acute migraine treatment and a drug called Placebo Oral Tablet for people with headache, migraine, migraine without aura, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGActive drug for acute migraine treatment

Standard dose of Sumatriptan 100 mg, which is used as an acute treatment for episodic migraine

DRUGPlacebo Oral Tablet

Inactive placebo pill (100 mg) looking like the active drug


Locations(2)

Dept. of Psychology and Behavioural Sciences

Aarhus C, Denmark

Department of Neurology, Aarhus University Hospital

Aarhus N, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06617832


Related Trials